According to GlobalData’s medical device pipeline database, 140 Aesthetic Injectables devices are in various stages of development globally. GlobalData’s report Aesthetic Injectables provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
Of these devices, 94 are in active development, while the remaining 53 are in an inactive stage of development. There are 30 products in the early stages of development, and the remaining 64 are in the late stages of development.
Aesthetic Injectables refer to gel-like substances that are injected beneath the skin to restore a more youthful appearance. Aesthetic Injectables achieve providing a more youthful appearance by increasing the volume of sunken cheeks or temples, reducing lines around nose and mouth (marionette lines and smile lines), plumping up lips and enhancing facial contour. Aesthetic Injectables are grouped into segments based on their molecular composition. Aesthetic injectables include Botulinum Toxin type A, Hyaluronic Acid (HA) fillers, and Non-Hyaluronic Acid fillers. One unit refers to one Aesthetic Injectable.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Aesthetic Injectables pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Aesthetic Injectables devices. Overall, most of these Aesthetic Injectables pipeline devices are being developed by private entities.
Key players involved in the active development of Aesthetic Injectables include Allergan Aesthetics, LG Chem, Evolus, Hugel, Sinclair Pharma, BioPlus, Advanced Aesthetic Technologies, Dongkook Pharmaceutical, Bioxis Pharmaceuticals and Aesthetic Medical Device.
For a complete picture of the developmental pipeline for Aesthetic Injectables devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
